[
  {
    "ts": null,
    "headline": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
    "summary": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
    "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748218034,
      "headline": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
      "id": 134697300,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453973904/image_1453973904.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
      "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce"
    }
  }
]